Cointime

Cogent Biosciences

company

About

Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.

  • 101 - 250

Highlights

Total Funding Amount
$65M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$65M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
101 - 250
Operating Status
Active

Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$65M
Cogent Biosciences has raised a total of $65M in funding over 2 rounds. Their latest funding was raised on Jun 11, 2015 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 11, 2015 Series B $65M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Cogent Biosciences is funded by 1 investors. Seagen are the most recent investors.
Investor Name Lead Investor Funding Round
Seagen — Series B
Cointime
เนื้อหา
บริษัท